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Abstract
Unconjugated bilirubin, the end product of heme catabolism and antioxidant, induced brain 
damage in human neonates is a well-recognized clinical syndrome. However, the cellular and 
molecular mechanisms underlying bilirubin neurotoxicity remain unclear. To characterize the 
sequence of events leading to bilirubin-induced neurotoxicity, we investigated whether bilirubin-
induced glial activation was involved in bilirubin neurotoxicity by exposing co-cultured rat glial 
cells and cerebellar granule neurons (CGN) to bilirubin. We found that bilirubin could markedly 
induce the expression of TNF-α and iNOS in glial cells, and even at low concentrations, the co-
culture of glial cells with neurons significantly enhances neurotoxicity of bilirubin. Pretreatment 
of the co-cultured cells with minocycline protected CGN from glia-mediated bilirubin 
neurotoxicity and inhibited overexpression of TNF-α and iNOS in glia. Furthermore, we found 
that high doses of bilirubin were able to induce glial injury, and minocycline attenuated bilirubin-
induced glial cell death. Our data suggest that glial cells play an important role in brain damage 
caused by bilirubin, and minocycline blocks bilirubin-induced encephalopathy possibly by directly 
and indirectly inhibiting neuronal death pathways.
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1. Introduction
Minocycline is a semisynthetic second-generation tetracycline with neuroprotective, 
antioxidant, and anti-inflammatory effects that are completely distinct from its antimicrobial 
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actions (Shultz and Zhong, 2017). This compound could directly inhibit free radical 
production as well as exhibit free-radical scavenging activity (Kraus et al., 2005). 
Interestingly, in addition to showing minocycline protects brains against many brain injury 
insults through the anti-oxidant mechanism (Shultz and Zhong, 2017), we also clearly show 
that minocycline can markedly attenuate brain damage induced by excess bilirubin, a 
physiological antioxidant in Gunn rats (Lin et al., 2005).
Bilirubin is a catabolic end product of heme metabolism and is excreted from the liver via 
conjugating with glucuronide by hepatic glucuronyl transferase. Conjugation solubilizes free 
bilirubin in water and reduces the serum levels of unconjugated bilirubin. Normally, 
bilirubin is a physiologic antioxidant (Baranano et al., 2002; Dore and Snyder, 1999; Stocker 
et al., 1987) and mildly increased blood bilirubin is able to lower the risk for ischemic stroke 
and coronary artery disease (Djousse et al., 2001; Perlstein et al., 2008; Schwertner et al., 
1994). Most recently, it has been demonstrated that bilirubin’s redox activity could directly 
prevent excitotoxicity and neuronal death by scavenging O2· – (Vasavda et al., 2019). 
However, in the neonate, failure of the bilirubin excretion pathway or its conjugation in the 
liver can result in an accumulation of unconjugated bilirubin leading to hyperbilirubinemia 
(Gourley, 1997). Neonatal jaundice is usually the consequence of a transient deficiency of 
bilirubin conjugation caused by breast-feeding, prematurity, glucose-6-phosphate 
dehydrogenase (G6PD) deficiency, or a variety of hemolytic diseases (Kaplan and 
Hammerman, 1998). Toxic levels of unconjugated bilirubin are also encountered in adults 
with recessively inherited Crigler-Najjar type I disease (Ebrahimi and Rahim, 2018; Erlinger 
et al., 2014; Green and Gollan, 1997; Rossi et al., 2005). Severe hyperbilirubinemia can 
cause bilirubin-induced neurologic dysfunction, potentially leading to permanent brain 
damage (Yueh et al., 2017). It is often associated with characteristic neuropathology and 
neurodegeneration of the cerebellum (particularly loss of Purkinje cells and granule 
neurons), the basal ganglia, hippocampus, and cochlear nucleus (Bortolussi et al., 2015; 
Dennery et al., 2001).
The exact cellular and molecular mechanisms underlying bilirubin-induced brain damage are 
currently poorly understood. It has been shown in neurons, high levels of bilirubin interfere 
with DNA and protein synthesis, interact directly with cell membrane phospholipids and 
alter intracellular pH (Chuniaud et al., 1996; Dennery et al., 2001; Rodrigues et al., 2002; 
Rosenstein et al., 1983). Additionally, bilirubin inhibits several mitochondrial enzymes 
(Dennery et al., 2001) and Ca2+-mediated calmodulin kinase activity (Machaca, 2003; 
Rodrigues et al., 2002), as well as activates the function of the N-methyl-D-aspartate 
(NMDA) receptor (Chen et al., 2016; Hoffman et al., 1996; McDonald et al., 1998) and p38 
MAP kinase phosphorylation (Lin et al., 2005; NaveenKumar et al., 2015). Furthermore, 
many reports demonstrated that bilirubin also directly induced glial death (Brites et al., 
2009; Feng et al., 2018; Kumral et al., 2005; Vodret et al., 2017). It appears that neurons are 
more vulnerable to bilirubin toxicity than astrocytes (Silva et al., 2002), although astrocytes 
are more competent in releasing glutamate and inflammatory factors than neurons when 
exposed to bilirubin (Falcao et al., 2006).
Studies suggest that minocycline blocks neuronal death by inhibiting the release of 
cytochrome c and p38 MAP Kinase. Additionally, minocycline can also inhibit 
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inflammation from glia (Lin et al., 2005). However, it has never been shown whether 
minocycline also inhibits antioxidants, such as bilirubin-induced neuronal death and 
inflammation. Given the potential therapeutic efficacy of minocycline on 
hyperbilirubinemia, understanding its neuroprotective mechanism(s) underlying this disease 
is of great importance.
Inflammatory factors such as the inducible nitric oxide (iNOS) and cytokines including 
TNF-α play key roles in brain injury (Lee et al., 2004) and, if the secretion is imbalanced, 
are detrimental to neurons (Xie et al., 2004). Currently, there is no direct evidence to support 
that glial cells are directly involved in bilirubin-induced neuronal death.
In the present study, we demonstrate that bilirubin as a physiological antioxidant can induce 
the expressions of TNFα and iNOS in glia and such inductions can be blocked by 
minocycline. Additionally, bilirubin is able to induce neuronal death in the mixed culture of 
CGN and glial cells even at subtoxic levels. Pretreatments of CGN with minocycline 
significantly attenuated bilirubin-induced neuronal death in the presence of glia. 
Furthermore, bilirubin at high doses was able to induce glial death and minocycline could 
block bilirubin-induced glial toxicity. Our data demonstrate that bilirubin induced CGN 
neuronal death could be potentiated by glia, especially at lower doses and minocycline is 
able to block bilirubin-induced glial activation and death, as well as glia-mediated neuronal 
death.
2. Materials and methods
2.1. Primary culture of CGN and glial cells
CGN and glial cells used in this study were prepared from 8-day-old Sprague-Dawley rat 
pups (Harlan Laboratories, IN) as previously described (Du et al., 2001). Briefly, freshly 
dissected cerebella were dissociated in the presence of trypsin and DNase I and planted on 
poly-L-lysine coated dishes. Cells were seeded at a density of 1.5 × 106 cells/ml in basal 
medium Eagle supplemented with 10 % FBS, 25mM KCl, and gentamicin (0.1 mg/ml). For 
glial cell culture, 3 days later, the cells were passaged once to get rid of neurons. The mixed 
glial cultures were grown in this culture medium for two weeks and the glial cells were then 
passaged twice for experiments. For co-culture experiments, CGN at 1.5 × 106 cells/ml were 
cultured onto removable 10-mm Nunc tissue inserts with treatments with cytosine 
arabinoside (10 μM) 24 h after initial plating. When the glial cells reach confluence, the 
inserts containing 10-day cultured CGN were placed onto wells containing glial cells and 
used for the experiments immediately. Viable neurons will be quantified by counting 
fluorescein (green) positive cells which result from the de-esterification of fluorescein 
diacetate (FDA) by living neurons in inserts (Du et al., 2001). The viability of glial cells was 
quantified by using MTT (Du et al., 2003). Values are expressed as a % of control cultures 
for each experiment and the data is represented as the mean ± standard error of replicate 
experiments.
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2.2. Western blot analysis
Western blot was performed on whole-cell extracts (10 μg) that were prepared by lysing 
cells in RIPA buffer containing 1 % Nonidet P-40, 0.1 % SDS, 50mM Tris (pH 8.0), 50mM 
NaC1, 0.05 % deoxycholate, and protease inhibitor (Roche, Indianapolis). Proteins were 
size-fractionated (SDS-PAGE) on a 4–12 % polyacrylamide gradient gel and transferred 
onto nitrocellulose (Hybond N, Amersham, CA, USA). The blots were then probed with 
polyclonal antibodies specific for TNFα, iNOS, and β-actin (Santa Cruz, CA) followed by 
horseradish peroxidase-linked antibodies (Santa Cruz, CA). Bound antibody was visualized 
using enhanced chemiluminescence (Amersham, Arlington Heights, IL).
3. Results
3.1. Minocycline treatments blocked bilirubin-induced expression of iNOS and TNFα in 
primary rat glial cells
In order to examine whether bilirubin affected expressions of iNOS and TNFα in glial cells, 
we incubated primary rat glial cells with 1μM bilirubin (equivalent to 0.625 μg/ml) for 24 h. 
iNOS and TNFα expression in glial cells were measured by western blot. After incubation 
of bilirubin, the iNOS levels were increased by 292.2 ± 16.6 % as compared to control cells 
(p < 0.001). TNFα levels were also significantly induced (455.3 ± 46.9 %) as compared to 
controls (p < 0.001) (Fig. 1). Pretreatments of cells with minocycline (10 μM) significantly 
inhibited bilirubin-induced expressions of iNOS (from 292.2 ± 16.6 % to 158.2 ± 16.39 %, p 
< 0.01) and TNFα (from 455.3 %±46.9% to 190.4 ± 52.2 %, p < 0.01) (Fig. 1).
3.2. Glia enhances bilirubin-induced CGN neuronal death, and minocycline exerts 
neuroprotection
To further examine whether minocycline protects CGN against glia-mediated bilirubin 
neurotoxicity, we treated co-cultures of glia and CGN with bilirubin and minocycline. As 
shown in Fig. 2A, we have found that glial cells significantly enhance neuronal death from 
81.4 ± 8.4% to 62.5 ± 7.6 % (p < 0.05) and 71.2 ± 8.8% to 45.5 ± 10.6 % (p < 0.05) 
followed by exposure of co-cultures to 1 μM and 2 μM bilirubin for 24 h. Pretreatment of 
cells with minocycline significantly attenuated 1 μM bilirubin-induced neuronal death (p < 
0.05) (Fig. 2B).
3.3. Minocycline attenuates bilirubin-induced glial cell death
Interestingly, exposure of primary glial cells to bilirubin at 1 μM and 2 μM did not s induce 
cell death. In contrast, 5 μM and 10 μM bilirubin markedly induced primary glial cell death 
as compared with the control group (Fig. 3A). 2h pretreatment of minocycline (10 μM) 
significantly blocks bilirubin (5 μM) -induced glial death (from 48.5 ± 1.3% to 93.5 ± 2.5 %, 
Fig. 3B).
4. Discussion
Although bilirubin is a well-recognized neurotoxin for neonates, the cellular mechanisms 
underlying its toxicity are poorly understood. Additionally, how minocycline protects cells 
against the neurotoxicity of bilirubin, a physiology antioxidant, remains to be elucidated. 
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Glial activation is observed in many neurodegenerative disorders (Chen et al., 2010; Lull and 
Block, 2010) and usually mediated by free radicals (McGeer and McGeer, 1998; von 
Bernhardi et al., 2015). Here, by using a co-culture system, we demonstrated that glial cells 
could be activated by anti-oxidant bilirubin and activated glial inflammation greatly 
enhanced neuronal death induced by bilirubin at sub toxic levels (1 and 2 μM), as compared 
to without glial involvement. Minocycline blocks bilirubin-induced neuronal death in the 
absence or presence of glia. Interestingly, bilirubin at 1 μM induced expression of 
inflammatory factors, iNOS, and TNFα, but did not significantly induce glial cell death. 
This finding indicates that bilirubin at lower doses induces neurotoxicity possibly via the 
activation of glia. At high doses, bilirubin directly induces both neuronal and glial cell death. 
Minocycline not only blocks bilirubin-induced CGN neuronal death as we previously 
reported but also blocks bilirubin-induced glial cell death. To the best of our knowledge, our 
findings are the first to demonstrate that antioxidant bilirubin could directly activate glia and 
glial activation potentiates bilirubin neurotoxicity. Minocycline significantly protects both 
neurons and glial cells from bilirubin toxicity. The fact that glial activation enhances CGN 
neurotoxicity when treated with bilirubin, suggests that neuroprotective therapeutic 
development has to consider effects of bilirubin-induced glial activation/inflammation on 
neuronal death as both are the major cause for kernicterus in mild hyperbilirubinemia, 
although in severe bilirubinemia, bilirubin can directly induce glial and neuronal death. In 
summary, data obtained from this study explain, at least partially, why minocycline is so 
protective in the treatment of hyperbilirubinemia in vivo and suggest that minocycline not 
only inhibits free radical, but also antioxidant-induced neurotoxicity. Our results may lead to 
the development of new therapies for the treatment of both mild and severe 
hyperbilirubinemia.
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Fig. 1. Minocycline treatments blocked bilirubin-induced expressions of TNFα and iNOS in rat 
cerebellar glia.
Mixed glial cells were pretreated with or without minocycline (10 μM, 2h) followed by 
bilirubin (1 μM) treatments for additional 24 h (BR + M vs. BR). The lysates were 
immunoblotted with anti-iNOS and TNFα antibodies. The anti-β-actin antibody was used to 
confirm an equal amount of protein loading in each gel lane. All cultures were treated in 
triplicate at the indicated times and data are represented as the mean ± SEM (### p < 0.001, 
treated with bilirubin vs. control; ** p < 0.01, treated with minocycline and bilirubin vs. 
bilirubin only by Student’s t-test). This experiment was repeated three times.
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Minocycline is able to block inflammation-mediated bilirubin-induced neurotoxicity. A. Glia 
potentiates subtoxic bilirubin-induced CGN neuronal death. Rat CGN in the insert were co-
cultured on the confluent layer of glia for 10 days and then treated with bilirubin (0.5–2 μM) 
for additional 24 h. Neuronal viability in the inserts was assessed by FDA, as compared to 
pure CGN cultures. All cultures were treated in triplicate at the indicated times and data are 
represented as the mean ± SEM (*p < 0.05, treated vs. control by Student’s t-test). This 
experiment was repeated three times with similar results. B. Minocycline protects CGN 
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against glia-mediated bilirubin neurotoxicity. Rat CGN in the insert co-cultured with glia 
were pretreated with minocycline (10 μM) followed by the bilirubin (1 μM) treatments. 
Neuronal viability in the inserts was assessed by FDA. All cultures were treated in triplicate 
at the indicated times and data are represented as the mean ± SEM (*p < 0.05, treated with 
minocycline vs. bilirubin only by Student’s t-test). This experiment was repeated three times 
with similar results.
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Fig. 3. Minocycline attenuates bilirubin-induced glial cell death.
A. Rat cerebellar glia were treated with bilirubin (0.5–10 μM) for 24 h. B. Cerebellar glia 
were pretreated with minocycline (10 μM) for 2h followed by 24 h bilirubin treatments 
(5μM). Cell viability was assessed by MTT. All cultures were treated in triplicate at the 
indicated times and data are represented as the mean ± SEM (N,S, not significant, **p < 
0.01, ***p < 0.001 treated vs. control by Student’s t-test). This experiment was repeated 
three times with similar results.
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